Bone Mineral Density in Survivors of Childhood Cancer: A Meta-Analysis.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
30 Jul 2024
Historique:
received: 02 02 2024
revised: 30 04 2024
accepted: 02 05 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: aheadofprint

Résumé

There is an increasing population of childhood cancer survivors (CCS) at risk for treatment-related toxicities, including skeletal morbidities. Bone mineral density (BMD) is a proxy for bone health and reductions are associated with osteoporosis and fractures. To investigate bone health in CCS by conducting a systematic review and meta-analysis of BMD after completed treatments. We searched Medline, Embase, Cochrane, and Web of Science in May 2019 and updated in May 2023. Studies reporting BMD Z-scores measured with dual-energy x-ray absorptiometry in CCS after treatment completion. We performed a pooled analysis of studies reporting BMD Z-scores and thereafter we analyzed studies comparing BMD in survivors and healthy controls. All analyses were performed based on the site of BMD measurement. Of 4243 studies, 84 were included (N = 8106). The mean time off-treatment across the studies ranged from 2 months to 24 years. The overall pooled mean Z-score was -0.57 (95% confidence interval [CI] -0.59 to -0.55) in the whole-body, -0.84 (95% CI -0.86 to -0.83) in the lumbar spine, -0.79 (95% CI -0.81 to -0.77) in the femoral neck and -0.14 (95% CI -0.18 to -0.11) in the total hip. When comparing survivors with controls, BMD was significantly lower in survivors at all sites. English publications, study-level meta-analysis. We showed a significant reduction of BMD Z-scores in CCS. Given the increased fracture risk already within -1 SD, these results emphasize the need for BMD surveillance and secondary prevention in CCS.

Identifiants

pubmed: 39076127
pii: 198032
doi: 10.1542/peds.2024-066081
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

CONFLICT OF INTEREST DISCLOSURES: The authors have no conflicts of interest relevant to this article to disclose.

Auteurs

Lilly Velentza (L)

Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Panagiotis Filis (P)

Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

Mari Wilhelmsson (M)

Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Per Kogner (P)

Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Nikolas Herold (N)

Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Lars Sävendahl (L)

Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Classifications MeSH